The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.d

Lupus - Lupus syndrome (see also Vd)

Publications

Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, Lunt M, Watson K, BSRBR-RA*, BSRBR-RA Control Centre Consortium*, Symmons DP, Hyrich KL

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.

RMD open. 2017;3(1):e000314

Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M, BIOGEAS study group

Biologics-induced autoimmune diseases.

Current opinion in rheumatology. 2013;25(1):56-64

Chang C, Gershwin ME

Drug-induced lupus erythematosus: incidence, management and prevention.

Drug safety. 2011;34(5):357-74

Williams VL, Cohen PR

TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.

International journal of dermatology. 2011;50(5):619-25

Hamzaoglu H, Cooper J, Alsahli M, Falchuk KR, Peppercorn MA, Farrell RJ

Safety of infliximab in Crohn's disease: a large single-center experience.

Inflammatory bowel diseases. 2010;16(12):2109-16

Beigel F, Schnitzler F, Paul Laubender R, Pfennig S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S

Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.

Inflammatory bowel diseases. 2011;17(1):91-8

De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X, Club Rhumatismes et Inflammation

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.

Arthritis research & therapy. 2005;7(3):R545-51

Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

Gastroenterology. 2003;125(1):32-9